The Latest Breaking News from Lilly

U.S. health officials have approved a new Alzheimer’s drug that can modestly slow the disease

Mega-cap stocks are the flavor of the season, and these three big names are the next set of contenders racing towards the $1 trillion market cap club.

Research raises possibility that tirzepatide could become first pharmaceutical treatment for the sleeping disorder

The World Health Organization and drugmaker Eli Lilly and Co. are warning patients to be wary of fake versions of weight-loss and diabetes medicines

Federal health advisers have endorsed a closely watched Alzheimer’s drug from Eli Lilly for people with mild dementia

Most CFOs have more options than they think, according to an expert.

Ashkenazi is a 23-year veteran of Eli Lilly and Company.

Ashkenazi will have the task of investing in the company’s next wave of growth in the AI era.

Discover why Eli Lilly is considered a 'strong buy' as it capitalizes on the growing demand for diabetes and obesity treatments, backed by its robust financial performance and promising future prospects.

Amid increasing healthcare spending, breakthroughs in genomics and personalized medicine, and the adoption of new technologies, the pharma industry is booming. So, let’s analyze Eli Lilly (LLY) and Pfizer (PFE) to determine which pharma stock will surge from their first-quarter earnings. Read on to find out.

Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.